Sitagliptin Phosphate Tablet, Film Coated
Product Images NDC 0781-5770

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sitagliptin Phosphate (NDC 0781-5770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sita-25-mg (25mg30slabel)

Sitagliptin Tablets, USP 25 mg film-coated tablets packaging label by Sandoz Inc. It contains 30 tablets per package and includes a note to dispense the accompanying Medication Guide to each patient. The label states the active ingredient is sitagliptin phosphate equivalent to 25 mg sitagliptin and provides storage and usage instructions.*

FDA Label Image

Sita-50-mg (50mg30slabel)

Sitagliptin Tablets USP 50 mg film-coated tablets label carton by Sandoz Inc. The package contains 30 tablets. The label includes dosage information, storage instructions, and a pharmacist dispensing note. Manufactured by Sandoz Private Limited, India. NDC 0781-5768-31.*

FDA Label Image

Chemicalstructureformula (Image 01)

Chemical structure of sitagliptin phosphate, the active ingredient in Sitagliptin Phosphate oral tablets. The diagram shows the molecular arrangement including fluorine atoms, amino group, piperazine ring, and trifluoromethyl group, along with phosphate and water molecules.*

FDA Label Image

Figure1 (Image 02)

A line graph depicting the least squares mean change from baseline over 21 weeks for various treatment groups including Placebo, Metformin 500 mg b.i.d., Metformin 1000 mg b.i.d., Sitagliptin 100 mg q.d., Sitagliptin 50 mg b.i.d. with Metformin 500 mg b.i.d., and Sitagliptin 50 mg b.i.d. with Metformin 1000 mg b.i.d. The x-axis represents weeks, and the y-axis shows the change from baseline.*

FDA Label Image

Figure2 (Image 03)

A line graph showing the least squares (LS) mean change from baseline over 52 weeks, comparing Sitagliptin 100 mg and Glipizide. The x-axis is labeled 'Week' and the y-axis is labeled 'LS Mean Change from Baseline.' Both treatments show a decline initially, reaching around -0.9 by week 30, with slight increases toward week 52.*

FDA Label Image

Sita-100-mg (Image 04)

Label for Sitagliptin Tablets USP 100 mg by Sandoz Inc, containing 30 film-coated tablets. The label includes dosing storage instructions and a note for pharmacists to dispense the accompanying Medication Guide. Manufactured by Sandoz Private Limited, India, with NDC 0781-5770-31.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.